California Controversy: Let's Not Expand the Market in Women's Eggs
By Marcy Darnovsky and Susan Berke Fogel,
Huffington Post
| 09. 03. 2013
Last month, California Governor Jerry Brown vetoed a bill that would have allowed researchers to pay women for having their eggs harvested and retrieved. His move was warmly welcomed by women's health and public interest groups including Our Bodies Ourselves, National Women's Health Network, Pro-Choice Alliance for Responsible Research, Alliance for Humane Biotechnology and Center for Genetics and Society. (Disclosure: see author affiliations.)
Echoing the longstanding concerns of many progressives about the serious risks of egg retrieval, Governor Brown's brief but eloquent veto message recognized that "in medical procedures of this kind, genuinely informed consent is difficult because the long term risks are not adequately known." He also acknowledged that low-income women would face disproportionate temptations to discount the risks. "Putting thousands of dollars on the table only compounds the problem," Brown wrote.
The vetoed bill, AB 926, was sponsored by the fertility industry's trade organization, the American Society for Reproductive Medicine. It was supported by several mainstream women's organizations, and breezed through the Democratic-dominated legislature. Ironically, as Governor Brown noted, the law that this bill would have overturned...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...